Intensity Therapeutics, Inc. (INTS)
- Previous Close
0.3137 - Open
0.3200 - Bid --
- Ask --
- Day's Range
0.3155 - 0.4433 - 52 Week Range
0.2900 - 5.1000 - Volume
3,978,954 - Avg. Volume
340,100 - Market Cap (intraday)
7.157M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
www.intensitytherapeutics.comRecent News: INTS
View MorePerformance Overview: INTS
Trailing total returns as of 5/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INTS
View MoreValuation Measures
Market Cap
7.16M
Enterprise Value
6.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
21.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-123.08%
Return on Equity (ttm)
-298.57%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.01M
Diluted EPS (ttm)
-1.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
929k
Total Debt/Equity (mrq)
39.22%
Levered Free Cash Flow (ttm)
-6.34M